Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews

CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701

Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research